Trial Profile

A Phase II Study of Selinexor (KPT-330) in Patients With Advanced Thymic Epithelial Tumour (TET) Progressing After Primary Chemotherapy.

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 04 Jul 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Selinexor (Primary)
Indications Carcinoma; Liver metastases; Malignant thymoma; Thymic epithelial tumour; Thymoma
Focus Therapeutic Use
Acronyms TET-SEL

Most Recent Events

04 Jun 2024 Results of pooled analysis (NCT03193437 and NCT03466827 trials, n=31) assessing selinexor in patients with advanced thymoma and thymic carcinoma were presented at the 60th Annual Meeting of the American Society of Clinical Oncology.
13 Apr 2018 Planned number of patients changed from 25 to 50.
19 Mar 2018 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com